View Older Stories View More Recent Stories
-
Streetinsider.com's Hot Lunchtime Reads 10/28: (GT) (NE) (COH) (CRIS)
-
Curis' (CRIS) CUDC-907 IP Protection 'Strong' Following Latest Allowance - Roth Capital
-
Celator(R) Pharmaceuticals Announces Completion of Its Public Offering and the Exercise in Full of Option to Purchase Additional Units of Common Stock and Warrants to Purchase Common Stock
-
Roth Capital 'Impressed' with Ligand's (LGND) Q3 Results; Affirms at 'Buy'
-
Roth Affirms Cytokinetics (CYTK) at 'Buy'; Latest COSMIC-HF Enrollment Data is Encouraging
-
Stemline's (STML) Valuation is Compelling Heading into 'Data-Rich' 2015 - Roth Capital
-
Ligand's (LGND) Duavee Will be Significant N-T Revenue Driver; CHMP Opinion is Encouraging - Roth
-
Roth 'Encouraged' by Verastem's (VSTM) VS-6063 Effect on Biomarkers of CSCs
-
Roth Capital Downgrades IGI Laboratories (IG) to Neutral
-
Roth Capital 'Encouraged' by Cytori (CYTX) Receiving FDA Approval to Continue ATHENA
-
Roth Capital Lifts PT on Ligand (LGND) 32% Ahead of Q3 Results
-
Roth Affirms Ligand (LGND) at 'Buy' Following Strong Promacta Sales in Q3
-
Unusual 11 Mid-Day Movers 10/20: (SCOK) (ESI) (SHOR) Higher; (IBIO) (NCR) (CPXX) Lower
-
Roth Capital Maintains Cytokinetics (CYTK) at 'Buy' Following BENEFIT-ALS Update
-
Roth Capital Remains Bullish on Hudson Technologies (HDSN); EPA Ruling 'Materially' Better than Expected
-
Celator Pharmaceuticals (CPXX) Plans Common Stock, Warrants Offering
-
Celator(R) Pharmaceuticals Announces Public Offering of Common Stock and Warrants to Purchase Common Stock
-
Roth Boosts PT on Pharmacyclics (PCYC) to $188; Imbruvica Continues to Gain Traction
-
Roth Capital Remains Positive on Regeneron (REGN); Latest Outcome Better Positions Eylea as Superior DME Treatment
-
Roth Capital Positive on Curis (CRIS) Following Q3 Results from Roche/Erivedge
-
Roth Capital Adds MEI Pharma (MEIP) to Focus List; Multiple Key Inflection Points Coming
-
Roth Capital Downgrades Durata Therapeutics (DRTX) to Neutral
-
Roth Capital Starts The Hackett Group (HCKT) at Buy
-
New Pharmacyclics (PCYC) Collaboration Further Validates Imbruvica; Roth Boosts PT to $185
-
Roth Sees Visibility in Cytokinetics' (CYTK) CK-107 Program Increasing Significantly Moving Forward
-
NCE Status Won't Matter for Keryx Biopharma (KERX) - Roth Capital
-
Cytori Therapeutics (CYTX) Closes on $13.5M in Financing
-
Notable Analyst Rating Changes 10/10: (IPXL) (EA) (AON) Upgraded; (JCP) (GRPN) (BDSI) Downgraded
-
Roth Capital Resumes XOMA, Ltd. (XOMA) at Buy
-
Roth Capital Downgrades BioDelivery Sciences International (BDSI) to Neutral
-
ARI Network Services, Inc. Announces the Appointment of Chad J. Cooper to Board of Directors
-
Roth Positive on SolarCity's (SCTY) Loan Program; Sees Tail Risks Ebbing
-
Roth Capital Upgrades Golden Minerals Company (AUMN) to Buy
-
PlacementTracker Publishes Third Quarter 2014 PIPE Market League Tables
-
Cytori Therapeutics (CYTX) Announces $13.5M Registered Direct Placement
-
Roth Capital Cuts SodaStream International (SODA) to Neutral
-
Notable Analyst Rating Changes 10/7: (IR) (ADHD) (AAPL) Upgraded; (SNSS) (DE) (CBSH) Downgraded
-
Roth Keeps Regeneron (REGN) at 'Buy'; Another Eylea Approval is No Surprise
-
Roth Capital Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Neutral
-
Trina Solar (TSL) Closes 10.3M ADS, $115M Conv. Notes Offerings
-
Roth Capital Affirms SolarCity (SCTY) at 'Buy'; Comments on Recent Meetings with Management
-
Roth Capital Starts ContraFect Corp. (CFRX) at Buy; Market Missing Potential Impact of Bacteriophage Lysins
-
Recent Moves by Curis (CRIS) May Increase Value of CUDC-907 - Roth Capital
-
Trina Solar (TSL) Prices 10.3M ADS, $100M Conv. Notes Offering
-
Lerge Commercial Exit by RGS Energy (RGSE) is 'Right Move' - Roth
-
Latest Data for Regeneron's (REGN) Dupilumab Broadens Benefit Profile - Roth
-
Roth Lowers Ests on Galena Biopharma (GALE) Following Special Committee Report
-
Streetinsider.com's Hot Lunchtime Reads 9/29: (AAPL) (JACK) (BLRXX) (TSLA)
-
Daiichi Sankyo, Ambit (AMBI) Deal is Positive for BioLineRx (BLRX) - Roth Capital
-
Roth Maintains Keryx Biopharma (KERX) at Buy Following Initiation of Ferric Citrate Phase 2

